ArticleJournal of nanobiotechnology2025
Spikey biodegradable MXene nanosheets with enhanced cellular internalization and stimuli-responsive drug delivery for synergistic cancer therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in ultrasound-activated nano-sonosensitizers for cancer treatment: a systematic review and meta-analysis.Ultrasonics sonochemistry · 2026Pooled it
- MXene-based CRISPR/Cas9 nanoplatform targeting FABP5 for ROS amplification and synergistic photothermal/photodynamic therapy of cervical cancer.Journal of nanobiotechnology · 2026Article
- Biocompatibility and immunomodulation of MXenes for targeted delivery of bioactive agents and drugs.Bioactive materials · 2026Review
- The Emerging Role of MXenes in Cancer Treatment.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Two-dimensional (2D) MXenes are promising theranostic nanoplatforms, but their limited drug-loading capacity and intracellular delivery hinder therapeutic efficacy. Here, we develop a spikey MXene (sMXene) nanosheet via a self-assembly strategy that enables the controlled growth of porous SiO2 on the MXene surface. Bis [3-(triethoxysilyl) propyl] tetrasulfide was also introduced into the reaction system to achieve the degradation of spikey MXene (dsMXene). The spikey SiO2 layer enhances drug loading and cellular uptake, while glutathione (GSH)-responsive biodegradability ensures targeted drug release. Leveraging the intrinsic photothermal properties of MXenes, dsMXenes enable combined photothermal-chemotherapy for precise tumor treatment. This study demonstrates the first application of spikey SiO2-coated MXene in osteosarcoma therapy, addressing drug resistance caused by exocytosis. Mimicking viral surface topography, dsMXene enhances intracellular drug delivery and enables tumor-specific, GSH-triggered release, overcoming chemoresistance. When loaded with doxorubicin, dsMXene has potent antiosteosarcoma effects both in vitro and in vivo, with minimal off-target toxicity. This innovative integration of spikey surface engineering and stimuli-responsive drug delivery introduces a transformative platform for future cancer therapies, broadening the scope of MXene-based biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.